Clinical trial
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With…
NCT03194542 · Celgene, Industry · Completed
Key facts
| NCT number | NCT03194542 |
|---|---|
| Title | A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence |
| Official title | A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Myelofibrosis, Anemia |
| Intervention type | Drug |
| Interventions | Luspatercept |
| Enrollment | 95 |
| Start date | Nov 15, 2017 |
| Primary completion | Jul 18, 2022 |
| Completion | Jul 18, 2022 |
| First posted | Jun 21, 2017 |
| Last update posted | Aug 24, 2023 |
| Countries | France, Italy, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: